Skip to main content

Agenus Inc. (AGEN)

NASDAQ: AGEN · IEX Real-Time Price · USD
5.30
-0.01 (-0.19%)
After-hours:Oct 15, 2021 7:52 PM EDT
5.31
-0.19 (-3.45%)
At close: Oct 15, 4:00 PM
Market Cap1.24B
Revenue (ttm)68.55M
Net Income (ttm)-225.94M
Shares Out222.91M
EPS (ttm)-1.13
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,988,573
Open5.57
Previous Close5.50
Day's Range5.28 - 5.57
52-Week Range2.50 - 6.79
Beta1.40
AnalystsStrong Buy
Price Target10.00 (+88.3%)
Est. Earnings DateOct 28, 2021

About AGEN

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; AutoSynVax, a synthetic neo-antigen; PhosPhoSynVax, a vaccine candidate to treat tumor; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company als...

IndustryBiotechnology
IPO DateFeb 4, 2000
CEOGaro Armen
Employees359
Stock ExchangeNASDAQ
Ticker SymbolAGEN
Full Company Profile

Financial Performance

In 2020, Agenus's revenue was $88.17 million, a decrease of -41.24% compared to the previous year's $150.05 million. Losses were -$180.91 million, 68.0% more than in 2019.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for Agenus stock is "Strong Buy." The 12-month stock price forecast is 10.00, which is an increase of 88.32% from the latest price.

Price Target
$10.00
(88.32% upside)
Analyst Consensus: Strong Buy

News

Agenus to Receive $20M Milestone Payment from Bristol Myers Squibb with Dosing of First Patient with its TIGIT Bispec...

LEXINGTON, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines de...

4 days ago - GlobeNewsWire

2 Stocks Set to Win From the Historic Malaria Vaccine Approval

But those wins probably won't be all that big.

Other symbols:GSK
4 days ago - The Motley Fool

Agenus to Present AGEN1181 Clinical Data at SITC

LEXINGTON, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines de...

2 weeks ago - GlobeNewsWire

Agenus' Combo Therapy Trial Shows Higher Responses In Cervical Cancer

Agenus Inc (NASDAQ: AGEN) presented final results from the Bal/Zal combination study at the European Society for Medical Oncology ( ESMO21 ) Virtual Conference 2021. Related:   Agenus Gains As Balstilim...

4 weeks ago - Benzinga

Combination of Balstilimab Plus Zalifrelimab Doubles Responses in 2L Cervical Cancer in Data to Be Presented at ESMO

LEXINGTON, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines design...

1 month ago - GlobeNewsWire

New Agenus Subsidiary, SaponiQx, Builds Innovative Adjuvant Platform and Forms Collaboration with Ginkgo Bioworks

Development of saponin molecules designed to provide high-efficacy and long-lasting protection for pandemic vaccines Development of saponin molecules designed to provide high-efficacy and long-lasting p...

1 month ago - GlobeNewsWire

Balstilimab Monotherapy Data Published in Gynecologic Oncology

LEXINGTON, Mass., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines de...

1 month ago - GlobeNewsWire

Hot Biotech Stocks That Deserve Your Attention In August 2021

Is it time to add biotech stocks to your list this year? The post Hot Biotech Stocks That Deserve Your Attention In August 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | Penny...

Other symbols:DVAXGTBP
2 months ago - PennyStocks

Why Agenus Fell by Over 4% on Monday

Investors were spooked by some ugly numbers in the company's latest earnings report.

2 months ago - The Motley Fool

Agenus (AGEN) Reports Q2 Loss, Misses Revenue Estimates

Agenus (AGEN) delivered earnings and revenue surprises of -54.17% and -36.75%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Recap: Agenus Q2 Earnings

Shares of Agenus (NASDAQ:AGEN) moved higher by 2.1% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 32.14% over the past year to ($0.37), whic...

2 months ago - Benzinga

Agenus Corporate Update and Second Quarter 2021 Financial Report

LEXINGTON, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines de...

2 months ago - GlobeNewsWire

Will Agenus (AGEN) Report Negative Earnings Next Week? What You Should Know

Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

MiNK Therapeutics Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering

NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- MiNK Therapeutics today announced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission ...

2 months ago - GlobeNewsWire

Why Agenus Stock Sank on Tuesday

A top company executive is stepping down in the very near future.

2 months ago - The Motley Fool

Agenus to Provide Corporate Update and Second Quarter 2021 Financial Report

Conference Call on Monday, August 9, 2021, at 8:30 a.m. ET Conference Call on Monday, August 9, 2021, at 8:30 a.m. ET

2 months ago - GlobeNewsWire

What Makes Agenus (AGEN) a Good Fit for "Trend Investing"

Agenus (AGEN) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Re...

2 months ago - Zacks Investment Research

Agenus Acquires 120 Acres in the Heart of the California Biomanufacturing Center in Vacaville

VACAVILLE, Calif., July 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. has purchased 120-acres in Vacaville's California Biomanufacturing Center from housing developer A.G. Spanos, a transaction that represen...

3 months ago - GlobeNewsWire

Agenus to Participate in Resistance-Focused Oncology Panel at the William Blair Biotech Focus Conference 2021

LEXINGTON, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designe...

3 months ago - GlobeNewsWire

Agenus Closes $200M Upfront BMS Collaboration and Announces FDA Acceptance of IND for Partnered Anti-TIGIT Bispecific...

LEXINGTON, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents which includes checkpoint antibodies, cell therapies, adju...

3 months ago - GlobeNewsWire

Moving Average Crossover Alert: Agenus (AGEN)

Agenus (AGEN) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

3 months ago - Zacks Investment Research

Agenus (AGEN) Is a Great Choice for "Trend" Investors, Here's Why

Agenus (AGEN) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our short...

3 months ago - Zacks Investment Research

Agenus to Participate in the Raymond James 2021 Human Health Innovation Conference

LEXINGTON, Mass., June 21, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designe...

3 months ago - GlobeNewsWire

Why Agenus Stock Is Marching Higher Today

The biotech took a major step toward becoming a commercial-stage cancer company.

3 months ago - The Motley Fool

Agenus Gains As Balstilimab US Application Accepted For Review In Cervical Cancer

The FDA has accepted for review Agenus Inc's (NASDAQ: AGEN) marketing application seeking approval for balstilimab for recurrent or metastatic cervical cancer with disease progression on or after chemot...

3 months ago - Benzinga